IRIS
CECCHERINI SILBERSTEIN, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 68.157
AS - Asia 10.693
EU - Europa 8.691
SA - Sud America 1.715
AF - Africa 250
OC - Oceania 36
Continente sconosciuto - Info sul continente non disponibili 27
Totale 89.569
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 67.854
SG - Singapore 5.565
CN - Cina 1.801
IT - Italia 1.409
BR - Brasile 1.386
RU - Federazione Russa 1.290
DE - Germania 1.110
HK - Hong Kong 959
VN - Vietnam 854
UA - Ucraina 815
IE - Irlanda 800
SE - Svezia 696
FR - Francia 564
FI - Finlandia 501
GB - Regno Unito 466
PL - Polonia 435
KR - Corea 432
JP - Giappone 292
CA - Canada 156
IN - India 155
NL - Olanda 139
ID - Indonesia 117
AR - Argentina 110
AT - Austria 108
ES - Italia 93
MX - Messico 93
BD - Bangladesh 91
ZA - Sudafrica 74
TR - Turchia 62
BE - Belgio 61
EC - Ecuador 50
CZ - Repubblica Ceca 48
IQ - Iraq 46
CO - Colombia 44
PH - Filippine 44
PK - Pakistan 38
UZ - Uzbekistan 36
CL - Cile 32
VE - Venezuela 29
AU - Australia 27
ET - Etiopia 27
CH - Svizzera 26
MA - Marocco 24
PY - Paraguay 23
KE - Kenya 20
PE - Perù 20
AE - Emirati Arabi Uniti 19
JO - Giordania 19
DZ - Algeria 18
CM - Camerun 17
LT - Lituania 17
RO - Romania 17
EU - Europa 16
MY - Malesia 16
SA - Arabia Saudita 16
EG - Egitto 15
IR - Iran 15
IL - Israele 14
GR - Grecia 12
KZ - Kazakistan 12
TW - Taiwan 12
JM - Giamaica 11
PT - Portogallo 11
UY - Uruguay 11
DO - Repubblica Dominicana 10
NG - Nigeria 10
TN - Tunisia 10
BG - Bulgaria 9
KG - Kirghizistan 9
NZ - Nuova Zelanda 9
BO - Bolivia 8
HN - Honduras 8
NP - Nepal 8
TH - Thailandia 8
AL - Albania 7
AO - Angola 7
AZ - Azerbaigian 7
DK - Danimarca 7
HR - Croazia 7
HU - Ungheria 7
OM - Oman 6
PA - Panama 6
XK - ???statistics.table.value.countryCode.XK??? 6
CI - Costa d'Avorio 5
GE - Georgia 5
LB - Libano 5
LK - Sri Lanka 5
NO - Norvegia 5
PS - Palestinian Territory 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BY - Bielorussia 4
CR - Costa Rica 4
CY - Cipro 4
DM - Dominica 4
LV - Lettonia 4
MD - Moldavia 4
MN - Mongolia 4
MT - Malta 4
RS - Serbia 4
SC - Seychelles 4
Totale 89.513
Salva come PNG Salva come JPEG
Città #
Woodbridge 17.829
Wilmington 17.453
Houston 14.243
Singapore 3.009
Fairfield 2.206
Ashburn 1.587
Chandler 1.376
Ann Arbor 1.360
San Jose 1.221
Hong Kong 936
Seattle 893
Beijing 761
Cambridge 719
Dublin 694
Jacksonville 660
Rome 512
Medford 493
Council Bluffs 457
Santa Clara 450
Dearborn 368
New York 367
Kraków 359
Los Angeles 337
The Dalles 318
Helsinki 288
Ho Chi Minh City 268
Tokyo 257
Lawrence 230
Hanoi 222
Moscow 221
Buffalo 170
Munich 163
San Diego 155
Milan 152
São Paulo 139
Lauterbourg 132
Menlo Park 125
Nuremberg 117
Dallas 106
Mülheim 103
Orem 103
London 102
Jakarta 85
Chicago 83
Phoenix 71
Zhengzhou 70
Boardman 65
San Francisco 63
Creede 59
Brussels 58
Frankfurt am Main 58
Vienna 55
Redondo Beach 54
North Bergen 53
Montreal 51
Brooklyn 48
Johannesburg 47
Warsaw 47
Denver 46
Chennai 45
Amsterdam 43
Lappeenranta 43
Palo Alto 43
Rio de Janeiro 43
Redwood City 42
Atlanta 40
Falls Church 40
Guangzhou 40
Toronto 40
Shanghai 38
Cedarhurst 35
Nanjing 35
Stockholm 35
Colorado Springs 33
Mountain View 33
Poplar 33
Da Nang 31
Belo Horizonte 30
Boston 30
Haiphong 30
University Park 30
Brno 29
Dong Ket 29
Norwalk 29
Mexico City 28
Manchester 27
Kunming 26
Tashkent 25
Verona 25
Brasília 24
Hefei 23
Engelhard 22
Hangzhou 22
Madrid 22
Mumbai 22
Washington 22
Columbus 21
Seoul 21
Baghdad 20
Curitiba 20
Totale 73.943
Salva come PNG Salva come JPEG
Nome #
Is there any potential for first-line etravirine use? Analysis from a large data set of antiretroviral therapy-naive HIV-infected patients undergoing resistance test 592
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 577
Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes 567
Molecular and structural aspects of clinically relevant mutations related to the approved non-nucleoside inhibitors of HIV-1 reverse transcriptase 547
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 533
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 532
Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors 524
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev 518
HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay 518
Comparative Analysis of Drug Resistance Among B and the Most Prevalent Non-B HIV Type 1 Subtypes (C, F, and CRF02_AG) in Italy 505
Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes 504
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso 504
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 503
Virologic correlates of adherence to antiretroviral medications and therapeutic failure 500
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients 489
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 487
Understanding HIV compartments and reservoirs 484
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 484
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 483
Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice 483
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 482
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues 478
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia 476
Novel drug resistance mutations in HIV: Recognition and clinical relevance 475
Effect of maraviroc on non-R5 tropic HIV-1: Refined analysis of subjects from the phase IIb study A4001029 474
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naive to the antiretroviral drugs 474
Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success? 474
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 473
Effective program against mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso 471
Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors 469
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients 463
Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure 463
Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking 461
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors 457
Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development 457
New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors 457
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 457
A boceprevir failure in a patient infected with HCV-genotype 1g: importance and limitations of virus genotyping prior to HCV protease inhibitor-based therapy 455
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen 455
The multifactorial pathways towards resistance to the cytosine analogues emtricitabine and lamivudine: Evidences from literature 452
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 451
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 450
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 447
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort 446
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 445
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 444
Incomplete APOBEC3G/F neutralization by HIV-1 Vif mutants facilitates the genetic evolution from CCR5 to CXCR4 usage 444
Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning 443
Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy 442
HIV fitness and resistance as covariates associated with the appearance of mutations under antiretroviral treatment 441
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens 441
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors 439
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 439
'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing 439
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin 438
Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria 437
Gene transfer in astrocytes: comparison between different delivering methods and expression of the HIV-1 protein Nef 435
The use of human immunodeficiency virus resistance tests in clinical practice 435
Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine 434
Dynamics of NRTI resistance mutations during therapy interruption 434
Molecular dynamics and free energy studies on the wild-type and mutated hiv-1 protease complexed with four approved drugs: Mechanism of binding and drug resistance 433
Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes 433
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure 432
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro 432
Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study 432
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 431
HIV-Infected Late Presenter Patients 430
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype 430
A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART. 430
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens. 427
Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy 426
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 426
Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation 426
The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs 425
Molecular diversity of HIV in Albania 425
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes 424
Genetic and Structural Analysis of HIV-1 Rev Responsive Element Related to V38A and T18A Enfuvirtide Resistance Mutations 423
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 422
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 421
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir 421
May some HCV genotype 1 patients still benefit from dual therapy? The role of very early HCV kinetics 420
Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages 418
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 418
HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design 416
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 416
Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients 415
Key genetic elements in HIV-1 gp120 V1,V2 and C4 domains tightly and differentially modulate gp120 interaction with the CCR5 and CXCR4 N terminus and HIV-1 antigenetic Potential 415
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 415
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 415
Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district 415
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations 414
From current status to optimization of HCV treatment: Recommendations from an expert panel 414
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 413
HIV-1 R5+ /X4- tropic viruses can be inhibited in vitro as well as in vivo by maraviroc: a refined analysis of patients enrolled in the Phase IIb study A4001029 412
Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors 411
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 411
Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: An observational study using pooled European cohort data 410
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 410
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 409
Overlapping Structure of HBV genome and immune selecting pressure are the main driving forces for HBV evolution 409
Totale 45.306
Salva come PNG Salva come JPEG
Categoria #
all - tutte 225.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 225.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021853 0 0 0 0 0 0 0 0 0 288 382 183
2021/20222.995 130 221 199 148 120 230 183 126 564 242 150 682
2022/20233.815 419 295 194 447 351 793 270 354 313 43 240 96
2023/20241.502 226 44 90 58 120 255 71 61 57 207 34 279
2024/20258.700 280 1.700 929 481 251 544 1.040 419 794 519 873 870
2025/202612.733 1.070 546 1.361 1.326 1.330 613 1.901 1.887 1.613 1.086 0 0
Totale 90.821